MCL1 and myelodysplastic syndrome: Using haematologic malignancy cell lines and samples from patients with myelodysplastic neoplasms treated with selinexor, we have identified XPO1, NF‐κB(p65), MCL‐1 and p53 protein levels as protein markers of response to XPO1 inhibitor therapy.